Nektar Therapeutics | NKTR - 销售收入



金融业
股票价格
USD
资产
USD 280.41M
现金及等价物
USD 15.12M
销售成本
USD 4.44M
流动资产
USD 266.27M
流动负债
USD 53.54M
债务
USD 0
股息收益率
0
EBIT
USD -19.09M
EBITDA
USD -31.81M
员工
137
EPS每股收益
USD -1.35
股本和储备
USD 89.83M
销售毛利
USD 21.81M
债务利息支出
USD 9.77M
利息收入
USD -0.18
贷款资金
USD 63.16M
市值
USD 12.72B
净收入
USD -36.08M
营业费用
USD 40.9M
营业利润
USD -19.09M
普通股股本
USD 20.38M
税前利润
USD -34.7M
销售收入
USD 21.81M
销售和管理费用
USD 10.17M
股票
USD 14.46M
贸易债权人
USD 10.77M
应收帐款人
USD 1.78M


销售 更改 日
Agios Pharmaceuticals USD 18.8M 1.17M 2026-03
ALKERMES USD 392.91M 8.41M 2026-03
Alterity Therapeutics Limited AUD 596.04K 584.66K 2025-12
Amgen USD 8.62B 1.28B 2026-03
Baxter International USD 2.7B 270M 2026-03
BioCryst Pharmaceuticals USD 406.56M 247.16M 2025-12
Biogen USD 2.25B 30M 2026-03
Bristol-Myers Squibb USD 11.49B 1.01B 2026-03
Cara Therapeutics USD 2.57M 1.11M 2025-03
Cipla INR 71.19B 5.78B 2026-06
Dr.Reddys Laboratories INR 80.71B 5.25B 2026-06
Eisai JPY 205.43B 14.51B 2026-03
Eli Lilly USD 19.8B 500M 2026-03
Exelixis USD 610.8M 12.14M 2026-03
Gilead Sciences USD 7B 930M 2026-03
GlaxoSmithKline GBP 7.63B 991M 2026-03
Grifols EUR 2B 306.7M 2026-03
Halozyme Therapeutics USD 377M 74.76M 2026-03
Incyte USD 1.27B 240M 2026-03
Ionis Pharmaceuticals USD 246M 43M 2026-03
Ironwood Pharmaceuticals USD 106.51M 58.8M 2026-03
Karyopharm Therapeutics USD 34.08M 3.54M 2025-12
MacroGenics USD 20.8M 20.43M 2026-03
Merck USD 16.29B 110M 2026-03
Nektar Therapeutics USD 21.81M 2.32M 2025-12
Neurocrine Biosciences USD 811M 5.5M 2026-03
Novartis USD 14.41B 1.3B 2026-06
Pfizer USD 14.5B 3.08B 2026-03
Roche Holding CHF 15.65B 274.5M 2025-12
Sarepta Therapeutics USD 730.8M 287.9M 2026-03
Takeda JPY 1.09T 100B 2026-03
Teva Pharmaceutical Industries USD 11.77B 2.86B 2026-03
Xencor USD 4.51M 23.73M 2026-03